Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact

 
• By Lucie Ellis-Taitt
Conference
Janssen reports data for Zytiga triplet in early-stage prostate cancer at ASCO 2017 • Source: Mary Jo Laffler

More from Clinical Trials

More from R&D